Optimising MS disease-modifying therapies: antibodies in perspective

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• A subset of multiple sclerosis (MS) patients treated with interferon beta (IFN β) develop neutralizing anti-IFN β antibodies (NABs).
• NAB development is influenced by factors including IFN β genetic structure, production methods, formulation, and dosage.
• Predicting NAB development is currently not possible, with most cases appearing within two years of therapy initiation.

Purpose of the Study:

• To explore the impact of NABs on IFN β efficacy in MS.
• To discuss strategies for preventing or reversing NAB development to enhance treatment outcomes.

Main Methods:

• Review of existing literature on IFN β immunogenicity and clinical efficacy in MS.
• Analysis of factors contributing to NAB formation and persistence.
• Exploration of potential strategies to mitigate NAB development.

Main Results:

• Persistent NABs are associated with reduced biological effects and clinical efficacy of IFN β in MS patients.
• Approximately one-third of NAB-positive patients may revert to NAB-negative status over time.
• IFN β efficacy is significantly better in NAB-negative patients compared to persistently NAB-positive patients.

Conclusions:

• Preventing or reversing NABs could substantially improve the overall efficacy of IFN β and other biological disease-modifying treatments (DMTs) for MS.
• Future clinical studies should consider strategies like manufacturing improvements, immunosuppression, tolerance induction, and deimmunization to manage NABs.
• Optimizing IFN β therapy requires focusing on NAB-negative patient cohorts and exploring methods to maintain this status.